EXOSC9: A Drug Target / Disease Biomarker (G5393)

Target Name: EXOSC9

NCBI ID: G5393

EXOSC9: A Drug Target / Disease Biomarker

EXOSC9 is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and heart. It is made up of 91 amino acids and has a calculated molecular weight of 10.9 kDa. EXOSC9 is involved in a number of cellular processes, including cell signaling, inflammation, and stress responses.

One of the most interesting aspects of EXOSC9 is its potential as a drug target. EXOSC9 has been shown to play a role in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

EXOSC9 has been shown to promote the growth and survival of cancer cells. In one study, researchers found that EXOSC9 expression was positively correlated with tumor growth and metastasis in breast cancer cells. They also found that inhibiting EXOSC9 expression led to a significant reduction in tumor growth and metastasis.

EXOSC9 has also been shown to be involved in the development and progression of neurodegenerative diseases. In one study, researchers found that EXOSC9 was expressed in the brains of individuals with Alzheimer's disease and that its expression was associated with the severity of the disease. They also found that EXOSC9 was expressed in the brains of individuals with Parkinson's disease and that its expression was associated with the severity of the disease.

EXOSC9 has also been shown to be involved in stress responses. In one study, researchers found that EXOSC9 was expressed in the hearts of rats and that its expression was increased in response to stress. They also found that inhibiting EXOSC9 expression reduced the hearts' stress response.

In addition to its potential as a drug target, EXOSC9 has also been shown to have potential as a biomarker. In one study, researchers found that EXOSC9 was expressed in the tissues of individuals with pancreatic cancer and that its expression was associated with the poor prognosis of the disease. They also found that EXOSC9 was expressed in the tissues of individuals with colorectal cancer and that its expression was associated with the poor prognosis of the disease.

Overall, EXOSC9 is a protein that has a unique structure and function. Its potential as a drug target and biomarker make it an attractive target for researchers to study and develop new treatments for a number of diseases. Further research is needed to fully understand its role in various diseases and to develop new treatments.

Protein Name: Exosome Component 9

Functions: Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. The catalytic inactive RNA exosome core complex of 9 subunits (Exo-9) is proposed to play a pivotal role in the binding and presentation of RNA for ribonucleolysis, and to serve as a scaffold for the association with catalytic subunits and accessory proteins or complexes. EXOSC9 binds to ARE-containing RNAs

More Common Targets